Your browser doesn't support javascript.
Anti-SARS-CoV-2 Antibody Responses in Convalescent Plasma Donors Are Increased in Hospitalized Patients; Subanalyses of a Phase 2 Clinical Study.
Terpos, Evangelos; Politou, Marianna; Sergentanis, Theodoros N; Mentis, Andreas; Rosati, Margherita; Stellas, Dimitris; Bear, Jenifer; Hu, Xintao; Felber, Barbara K; Pappa, Vassiliki; Pagoni, Maria; Grouzi, Elisavet; Labropoulou, Stavroula; Charitaki, Ioanna; Ntanasis-Stathopoulos, Ioannis; Moschandreou, Dimitra; Bouhla, Anthi; Saridakis, Stylianos; Korompoki, Eleni; Giatra, Chara; Bagratuni, Tina; Pefanis, Angelos; Papageorgiou, Sotirios; Spyridonidis, Alexandros; Antoniadou, Anastasia; Kotanidou, Anastasia; Syrigos, Konstantinos; Stamoulis, Konstantinos; Panayiotakopoulos, George; Tsiodras, Sotirios; Alexopoulos, Leonidas; Dimopoulos, Meletios A; Pavlakis, George N.
  • Terpos E; Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, 11528 Athens, Greece.
  • Politou M; Hematology Laboratory Blood Bank, Aretaieion Hospital, School of Medicine, National and Kapodistrian University of Athens, 11528 Athens, Greece.
  • Sergentanis TN; Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, 11528 Athens, Greece.
  • Mentis A; Public Health Laboratories, Hellenic Pasteur Institute, 11521 Athens, Greece.
  • Rosati M; Human Retrovirus Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702-1201, USA.
  • Stellas D; Human Retrovirus Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702-1201, USA.
  • Bear J; Institute of Chemical Biology, National Hellenic Research Foundation, 48 Vassileos Constantinou Ave., 11635 Athens, Greece.
  • Hu X; Human Retrovirus Pathogenesis Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702-1201, USA.
  • Felber BK; Human Retrovirus Pathogenesis Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702-1201, USA.
  • Pappa V; Human Retrovirus Pathogenesis Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702-1201, USA.
  • Pagoni M; Hematology Unit, Second Department of Internal Medicine, Attikon University General Hospital, School of Medicine, National and Kapodistrian University of Athens, 11528 Athens, Greece.
  • Grouzi E; BMT Unit, Department of Hematology and Lymphomas, Evangelismos General Hospital, 10676 Athens, Greece.
  • Labropoulou S; Department of Transfusion Service and Clinical Hemostasis, "Saint Savvas" Oncology Hospital, 11522 Athens, Greece.
  • Charitaki I; Public Health Laboratories, Hellenic Pasteur Institute, 11521 Athens, Greece.
  • Ntanasis-Stathopoulos I; Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, 11528 Athens, Greece.
  • Moschandreou D; Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, 11528 Athens, Greece.
  • Bouhla A; Department of Transfusion Service and Clinical Hemostasis, "Saint Savvas" Oncology Hospital, 11522 Athens, Greece.
  • Saridakis S; Hematology Unit, Second Department of Internal Medicine, Attikon University General Hospital, School of Medicine, National and Kapodistrian University of Athens, 11528 Athens, Greece.
  • Korompoki E; Blood Bank, Evangelismos General Hospital, 10442 Athens, Greece.
  • Giatra C; Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, 11528 Athens, Greece.
  • Bagratuni T; BMT Unit, Department of Hematology and Lymphomas, Evangelismos General Hospital, 10676 Athens, Greece.
  • Pefanis A; Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, 11528 Athens, Greece.
  • Papageorgiou S; Department of Internal Medicine, Sotiria General Hospital of Chest Diseases, 11527 Athens, Greece.
  • Spyridonidis A; Hematology Unit, Second Department of Internal Medicine, Attikon University General Hospital, School of Medicine, National and Kapodistrian University of Athens, 11528 Athens, Greece.
  • Antoniadou A; BMT Unit, University Hospital of Patras, School of Medicine, University of Patras, 26500 Patras, Greece.
  • Kotanidou A; Fourth Department of Internal Medicine, Attikon University General Hospital, School of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece.
  • Syrigos K; First Department of Critical Care Medicine and Pulmonary Services, Evangelismos General Hospital, School of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece.
  • Stamoulis K; Oncology Unit, Third Department of Medicine, School of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece.
  • Panayiotakopoulos G; Hellenic National Blood Transfusion Center, 13678 Athens, Greece.
  • Tsiodras S; Pharmacology Laboratory, School of Medicine, University of Patras, 26500 Patras, Greece.
  • Alexopoulos L; National Public Health Organization, 15123 Athens, Greece.
  • Dimopoulos MA; Fourth Department of Internal Medicine, Attikon University General Hospital, School of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece.
  • Pavlakis GN; National Public Health Organization, 15123 Athens, Greece.
Microorganisms ; 8(12)2020 Nov 28.
Article in English | MEDLINE | ID: covidwho-948911
ABSTRACT
We evaluated the antibody responses in 259 potential convalescent plasma donors for Covid-19 patients. Different assays were used a commercial ELISA detecting antibodies against the recombinant spike protein (S1); a multiplex assay detecting total and specific antibody isotypes against three SARS-CoV-2 antigens (S1, basic nucleocapsid (N) protein and receptor-binding domain (RBD)); and an in-house ELISA detecting antibodies to complete spike, RBD and N in 60 of these donors. Neutralizing antibodies (NAb) were also evaluated in these 60 donors. Analyzed samples were collected at a median time of 62 (14-104) days from the day of first symptoms or positive PCR (for asymptomatic patients). Anti-SARS-CoV-2 antibodies were detected in 88% and 87.8% of donors using the ELISA and the multiplex assay, respectively. The multivariate analysis showed that age ≥50 years (p < 0.001) and need for hospitalization (p < 0.001) correlated with higher antibody titers, while asymptomatic status (p < 0.001) and testing >60 days after symptom onset (p = 0.001) correlated with lower titers. Interestingly, pseudotype virus-neutralizing antibodies (PsNAbs) significantly correlated with spike and with RBD antibodies by ELISA. Sera with high PsNAb also showed a strong ability to neutralize active SARS-CoV-2 virus, with hospitalized patients showing higher titers. Therefore, convalescent plasma donors can be selected based on the presence of high RBD antibody titers.
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Prognostic study Language: English Year: 2020 Document Type: Article Affiliation country: Microorganisms8121885

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Prognostic study Language: English Year: 2020 Document Type: Article Affiliation country: Microorganisms8121885